---
layout: default
title: Sennosides
parent: 僅模型預測 (L5)
nav_order: 570
evidence_level: L5
indication_count: 6
---

# Sennosides
{: .fs-9 }

證據等級: **L5** | 預測適應症: **6** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Sennosides: From Constipation to Hypotrichosis Simplex of the Scalp

## One-Sentence Summary

Sennosides is an anthraquinone glycoside stimulant laxative, internationally used to treat constipation by promoting colonic motility. The TxGNN model predicts it may be effective for **Hypotrichosis Simplex of the Scalp**, but this prediction is currently supported by **0 clinical trials** and **0 publications**, and the model's own rationale notes no known biological pathway connecting the drug to this indication.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Constipation (stimulant laxative; not currently registered in Saudi Arabia) |
| Predicted New Indication | Hypotrichosis Simplex of the Scalp |
| TxGNN Prediction Score | 99.29% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data for sennosides is not available in the DrugBank record queried (flagged as a data gap). However, based on well-established pharmacological knowledge confirmed in the evidence pack's own rationale text, sennosides act as a stimulant laxative: after bacterial conversion in the colon, its active metabolites irritate the colonic mucosa and enteric nerve plexus, increasing peristalsis and bowel evacuation. This mechanism is entirely local to gastrointestinal motility, with negligible systemic absorption.

Hypotrichosis simplex of the scalp is a hereditary hair follicle disorder involving disrupted follicular cycling and keratinization, unrelated to gut motility or enteric neural signaling. There is no known overlap in target pathways, receptor systems, or tissue biology between the two conditions.

The evidence pack's own repurposing rationale for this candidate explicitly states there is no mechanistic support: the prediction is a pure TxGNN knowledge-graph embedding association (rank 10,379 among all drug-disease pairs), not a finding grounded in pharmacology, and no clinical or literature evidence currently exists to support it.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Saudi Arabia Market Information

Sennosides currently has no marketing authorization on record in Saudi Arabia (0 licenses; market status: not marketed).

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Key warnings, contraindications, and drug interaction data were not available in the sources queried — TFDA package insert retrieval and DDI database lookup both returned no results.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a high TxGNN similarity score, this candidate has zero supporting clinical trials or literature, no plausible mechanistic link between colonic stimulant laxative activity and hereditary hair follicle disorders, and the drug is not currently marketed in the target region. The evidence pack's own scoring already classifies this as L5/S0 with a Hold recommendation.

**To proceed, the following is needed:**
- Confirmed DrugBank/TFDA mechanism-of-action data for sennosides
- Saudi Arabia (SFDA) package insert with warnings, contraindications, and DDI profile
- Preclinical or mechanistic studies linking anthraquinone laxatives to hair follicle biology, if any exist
- Continued literature/trial surveillance, given current zero-evidence status across PubMed, ClinicalTrials.gov, and ICTRP

*Note: five other TxGNN-predicted indications for sennosides (congenital hypotrichosis milia, diffuse alopecia areata, open-angle glaucoma, primary hereditary glaucoma, and alopecia) were also reviewed and share the same L5/S0/Hold status — none have drug-specific clinical or literature evidence to date.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

